Amgen Inc. $AMGN Shares Sold by Modera Wealth Management LLC

Modera Wealth Management LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 2.0% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 102,431 shares of the medical research company’s stock after selling 2,080 shares during the period. Modera Wealth Management LLC’s holdings in Amgen were worth $33,527,000 at the end of the most recent quarter.

Other large investors have also made changes to their positions in the company. Board of the Pension Protection Fund purchased a new position in shares of Amgen in the 4th quarter worth $26,000. Olistico Wealth LLC purchased a new stake in Amgen during the 4th quarter worth $33,000. Holos Integrated Wealth LLC purchased a new stake in Amgen during the 4th quarter worth $37,000. Howard Hughes Medical Institute purchased a new stake in Amgen during the 2nd quarter worth $32,000. Finally, Cloud Capital Management LLC purchased a new stake in Amgen during the 3rd quarter worth $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of analysts recently weighed in on AMGN shares. Freedom Capital cut shares of Amgen from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 12th. Cantor Fitzgerald upped their price target on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th. Daiwa Securities Group upped their price target on shares of Amgen from $370.00 to $410.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Jefferies Financial Group started coverage on shares of Amgen in a research report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price target for the company. Finally, Guggenheim upped their price target on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Stock Performance

NASDAQ:AMGN opened at $342.57 on Tuesday. The company has a debt-to-equity ratio of 5.78, a current ratio of 1.14 and a quick ratio of 0.90. The firm has a 50-day moving average of $363.51 and a two-hundred day moving average of $333.65. The stock has a market cap of $184.67 billion, a P/E ratio of 24.07, a PEG ratio of 3.45 and a beta of 0.47. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same period in the prior year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Stockholders of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is 70.84%.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.